• BioCardia completed consultations with Japan's PMDA on application materials for its CardiAMP cell therapy for ischemic heart failure.
• The milestone advances CardiAMP toward a marketing approval application; the therapy remains subject to Japanese regulatory review.
• CardiAMP has been evaluated in three clinical trials involving more than 200 patient procedures, including two randomized, double-blind, placebo-controlled trials.
• The company targets initial patient treatments in Japan and commercial revenue in 2028.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioCardia Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-035408), on November 06, 2026, and is solely responsible for the information contained therein.